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Abstract
Background: Severe refractory asthma is a heterogeneous disease. We sought to determine statistical clusters from the
British Thoracic Society Severe refractory Asthma Registry and to examine cluster-specific outcomes and stability.
Methods: Factor analysis and statistical cluster modelling was undertaken to determine the number of clusters and their
membership (N= 349). Cluster-specific outcomes were assessed after a median follow-up of 3 years. A classifier was
programmed to determine cluster stability and was validated in an independent cohort of new patients recruited to the
registry (n = 245).
Findings: Five clusters were identified. Cluster 1 (34%) were atopic with early onset disease, cluster 2 (21%) were obese with
late onset disease, cluster 3 (15%) had the least severe disease, cluster 4 (15%) were the eosinophilic with late onset disease
and cluster 5 (15%) had significant fixed airflow obstruction. At follow-up, the proportion of subjects treated with oral
corticosteroids increased in all groups with an increase in body mass index. Exacerbation frequency decreased significantly
in clusters 1, 2 and 4 and was associated with a significant fall in the peripheral blood eosinophil count in clusters 2 and 4.
Stability of cluster membership at follow-up was 52% for the whole group with stability being best in cluster 2 (71%) and
worst in cluster 4 (25%). In an independent validation cohort, the classifier identified the same 5 clusters with similar patient
distribution and characteristics.
Interpretation: Statistical cluster analysis can identify distinct phenotypes with specific outcomes. Cluster membership can
be determined using a classifier, but when treatment is optimised, cluster stability is poor.
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Introduction
Severe refractory asthma is a heterogeneous multi-dimensional
disease and is a consequence of a variety of pathophysiological
mechanisms driven by complex interactions between the host and
environment [1–4]. Algorithmic cluster analysis, such as hierar-
chical and k-means clustering, has been used to determine severe
or severe refractory asthma phenotypes in adults [5–11] and
children [12] and these clusters have demonstrated clinical utility
with cluster-specific response to therapy [1]. However, these
analyses have several limitations including difficulties in determin-
ing the best fitting number of clusters, as they are algorithmic by
nature and do not rely on statistical inference to determine this
number [13]. More importantly, the longitudinal phenotypic
stability of described clusters in a clinical setting has not been
previously examined. One challenge is that most approaches to
clustering can only be applied to the data at a single time point and
thus may derive new and additional clusters at another time point
in the same population making the assessment of the repeatability
of cluster membership and phenotype stability impossible.
An alternative approach to determine partitioning of multivar-
iate data is to use statistical mixture models [14] and these have
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been applied in several disciplines such as gene-expression [15],
neurophysiology [16], and magnetic resonance imaging [17].
Mixture models are a family of statistical models that determine
the best fitting number of clusters or mixtures by comparing
models with differing number of mixtures or clusters using model
selection criteria to choose the best-fitting model such as the
Akaike information criterion [18] and the Bayesian information
criterion [19]. These models are less sensitive to outliers and less
sensitive to over fitting the data values than k-means and
hierarchical clustering [20]. In addition, classifiers that determine
cluster membership can be applied to the same population
repeatedly and across cohorts to define phenotypic stability.
Here we report in a multi-centre longitudinal observational
study of severe refractory asthma the application of statistical
clustering, determine phenotypic-specific changes over time and
define the consequent affects upon phenotype stability.
Materials and Methods
Ethics statement
Written informed consent for data entry and analysis from the
multi centres was obtained from all subjects and the study was
approved by each centre’s local ethics committee. Ethical approval
for the British Thoracic Society Difficult Asthma Registry across
sites was obtained from the Office for Research Ethics Committees
Northern Ireland (number 10/NIR02/37). In Leicester additional
ethics was also obtained from the Leicestershire, Northampton-
shire and Rutland ethics committee (REC 6307).
Subjects and protocol
Subjects were recruited from centres contributing data to the
British Thoracic Society Severe refractory Asthma Registry [21–
25]. Subjects were assessed using a standardised protocol that
included the recording of demographics, pulmonary function tests,
allergy assessment, and standardised blood panel, including
peripheral blood eosinophil count and total serum immunoglobuin
(IgE). Data was entered into an anonymised, secure, web-based
registry hosted by Dendrite Clinical Systems Ltd. Subjects in the
first dataset were from 4 centres the Regional Severe refractory
Asthma Service, Belfast City Hospital, Institute for Lung Health,
Glenfield Hospital, Leicester, Royal Brompton Hospital, London
and North West Lung Centre, Manchester. These subjects were
assessed at baseline and after a minimum of 1 year follow-up.
Subjects were clinically managed in accordance with local and
national guidelines to optimise asthma control, and minimize
future risk of exacerbations, lung function impairment and side-
effects to therapy. The characteristics of these subjects have been
described previously [21–25]. The severe refractory patients were
defined by being on oral steroids 50% of the year or on high dose
inhaled steroids plus add on medications either at baseline or
follow-up.
The second cross-sectional validation cohort was recruited from
7 centres including the original 4 centres as well as Gartnavel
Hospital and Stobhill Hospital in Glasgow, and the Heart of
England Hospital, Birmingham. Written informed consent for
data entry and analysis was obtained from all subjects and the
study was approved by each centre’s local ethics committee.
Statistical analysis
Statistical analysis was carried out in R programming language
and SPSS 10.0 for Windows. Multiple imputation algorithms were
undertaken to allow for missing values. Variables were selected for
use in the multiple imputation analyses that satisfied several
conditions; they had less than 30% missing data and the missing
data was either classified as missing completely at random or
missing at random [26]. In order to determine which variables
were deemed missing at random and not missing at random we
used prior knowledge from multiple clinicians to determine if data
missing was due to patient severity or due to random chance of
missing information in medical records. Severity is the key
mechanism for informative missing-ness for severe asthma as if
patients are too severe some of the measurements are contrain-
dicated. The cases in variables that were not missing due to
severity of asthma were included in the multiple imputation
algorithm.
This reduced the total number of variables to 23 variables on
which multiple imputation was carried out, see supplement for a
list of variables used and for more details on multiple imputation.
Multiple imputation can be carried out for up to 70% missing data
in some cases if the variables are missing completely at random,
missing at random or if there is no bias from missing samples [26].
The missing variables are predicted using regression equations and
5 missing values are added for each variable. This methodology
obtains less biased parameter estimates than removing the patients
with missing values or imputing with the mean [26]. The mi
package in R was used for the implementation of the missing data
prediction as it allowed for convergence of the model to be
checked. Convergence is checked for both model parameters and
data before deriving the missing values to obtain good practices
and good predictions for missing values see online supplement.
Factor analysis was carried out in SPSS using principal
component methodology with varimax rotation to determine
factor scores and eigen values for each factor. We use factor
analysis to determine underlying clinical processes. The underlying
processes can be thought of as the independent structure of the
data. The factor analysis was carried out using the available non-
categorical variables. The treatment variables oral steroid dose
and Beclomethasone Dipropionate (BDP) equivalent dose inhaled
corticosteroids were transformed into a ranked treatment variable
before factor analysis, with patients with the highest inhaled
steroid treatment and highest oral steroid dose having the highest
rank. The underlying factors from the factor analysis were saved as
variables describing independent asthma pathology using the
derived factor scores. The factor scores were then used as input
variables for the cluster analysis to determine sub-groups within
the differing asthma pathology.
The clustering was carried out using a two way cluster/mixture
analysis [27,28] model that compares models for 1 to 15 clusters
using the Bayesian information criterion. The input variables for
the cluster analysis were the output latent factors from the previous
factor analysis. A cluster analysis was carried out for each of the 5
imputed datasets with 5 cluster membership as outcomes. The 5
cluster membership were combined using the same two-way
cluster algorithm but for categorical data to obtain a global
average cluster membership, for the many steps of the multiple
imputation cluster analysis please see Figure E1 in File S1.
Comparisons between clusters were made using the most
appropriate test: one-way analysis of variance (ANOVA) for
normally distributed data, x2 -test for proportional data and
Kruskal-Wallis test for non-normally distributed variables. The
non-missing data for each variable was used when testing. The
follow up data was analysed by applying paired t-tests or Wilcoxon
matched pair signed rank tests as appropriate to determine
differences over time for each cluster, general estimating equations
(GEE) models were also used but not presented here.
After cluster membership is determined a classifier can be
created. A classifier uses cluster specific statistics such as the mean
and standard deviation of key variables to determine cluster
Cluster Analysis of the BTS Severe Asthma Registry
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membership for new patients, it is a stand-alone algorithm that
unlike the cluster analysis does not require the rest of the data to
predict cluster membership. The clinical variables used as inputs
depend on their predictive accuracy of cluster membership with
the best predictors being kept into the classifier. A function in R
was programmed to classify the patients into one of the five
clusters, based on the specific cluster multivariate parameters that
were found in the cluster analysis. Every cluster has a unique
multivariate distribution based on a subset of input parameters. A
patient is classified as belonging to the cluster with the most likely
cluster multivariate characteristics for that patient, without the
need of the rest of the data to determine cluster membership.
Once classified the patients (supervised) cluster classification was
compared with their original (unsupervised) cluster classification to
determine percentage accuracy at baseline and stability at follow-
up. The classifier was applied to a second dataset to determine if
the clusters were in similar proportions and had similar
characteristics to the original dataset. A p value of ,0.05 was
taken as the threshold of statistical significance. For further details
of the classifier see online supplement.
Results
Three-hundred and forty-nine subjects from 4 centres were
included in the baseline analysis. The criteria for selection of the
variables used in the factor analysis were thus: Variables had to
have less than 30% missing data in the original cohort and were
also non-categorical. Five factors were found for the continuous
variables using the Kaiser criteria for selection of the number of
factors. Five factors were found for the continuous variables, these
factors or aspects can be described as representing airflow
obstruction, exacerbation frequency, IgE/body mass index
(BMI), treatment scaling and peripheral blood eosinophilia
(Table 1). These five derived factor variables were used as input
variables in to the cluster analysis. The optimal number of clusters
that were identified for each multiple imputed dataset is shown in
Table E1 in File S1 with the BIC for each cluster model and
imputed dataset in Figure E2 in File S1. The cluster memberships
returned were all very similar with very similar number of clusters,
although as previously discussed removal of missing data would
give a more concrete cluster membership and number of clusters.
Only using patients that had no missing data would create a
selection bias.
Membership was taken from each imputed dataset and used as
a variable to carry out latent class analysis to determine mean
cluster membership. A five cluster model best described the
dataset. Their characteristics are as shown Table 2.
Cluster 1 comprised 34% of the cohort; had early onset, atopic
asthma with the highest intensive care (ITU) admissions, high
exacerbation frequency, half the subjects receiving regular
systemic corticosteroid therapy, and poor lung function but with
the greatest bronchodilator reversibility. Cluster 2 comprised 21%
of the cohort; was an obese, late onset group with frequent
exacerbations, over half the subjects receiving regular systemic
corticosteroid therapy, near normal lung function and the highest
depression score. The remaining three clusters comprised 15%
each of the overall population. Cluster 3 subjects were mainly non-
atopic with normal lung function, the fewest number of subjects
receiving systemic corticosteroid therapy and infrequent exacer-
bations. Cluster 4 was a late onset group, with a markedly elevated
peripheral blood eosinophilia and frequent exacerbations. Cluster
5 had the worst lung function and the highest proportion of
subjects receiving systemic corticosteroid therapy, but had the least
frequent exacerbations. The proportions of subjects in each cluster
varied between centres Table E2 in File S1.
Subjects were followed up for a median (interquartile range) 3.1
(1.9 to 5.5) years. The cluster-specific changes in clinical outcomes
at follow-up are as shown (Table 3 and Figure 1), GEE models
were also carried out and showed similar effects for the variables
but are not presented here. At follow-up the proportion of subjects
Table 1. Factor loading for continuous variables from first imputed data set, other factor analysis on the other 4 imputed datasets
showed similar structure and factor loading.
Continuous Factors
1 2 3 4 5
Airflow Obstruction Exacerbation IgE/Obesity Treatment scaling Blood Eosinophilia
Cumulative Percentage of
variance explained by factors
21.3% 37.5% 51.4% 62.6% 72.1%
BMI .050 .205 .651 .346 .005
Pre-bronchodilator FEV1 %
predicted
.990 2.004 2.012 2.070 2.031
Pre-bronchodilator FVC %
predicted
.784 2.036 2.338 .123 .139
Pre-bronchodilator FEV1/FVC .724 .109 .296 2.195 2.196
Blood eosinophils6109/L 2.067 .166 2.155 2.050 .819
Total IgEkU/L .070 .068 2.621 .058 .071
Exacerbation frequency
(number of rescue oral
steroid courses in last year)
.052 .796 2.063 .247 .092
Number of primary care visits
in last year
.013 .759 .069 .350 .010
Treatment 2.090 2.029 .067 .847 2.077
Age at onset of symptoms .043 2.225 .519 2.071 .572
doi:10.1371/journal.pone.0102987.t001
Cluster Analysis of the BTS Severe Asthma Registry
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e102987
T
a
b
le
2
.
C
lin
ic
al
ch
ar
ac
te
ri
st
ic
s
o
f
th
e
o
ri
g
in
al
B
T
S
se
ve
re
re
fr
ac
to
ry
as
th
m
a
cl
u
st
e
rs
.
A
ll
(N
=
3
4
9
)
C
lu
st
e
r
1
(N
=
1
1
7
;
3
4
%
)
‘E
a
rl
y
o
n
se
t,
a
to
p
ic
’
C
lu
st
e
r
2
(N
=
7
2
;
2
1
%
)
‘O
b
e
se
,
la
te
o
n
se
t’
C
lu
st
e
r
3
(N
=
5
2
;
1
5
%
)
‘n
o
rm
a
l
lu
n
g
fu
n
ct
io
n
,
le
a
st
se
v
e
re
a
st
h
m
a
’
C
lu
st
e
r
4
(N
=
5
4
;
1
5
%
)
‘l
a
te
o
n
se
t,
e
o
si
n
o
p
h
il
ic
’
C
lu
st
e
r
5
(N
=
5
4
,
1
5
%
)
‘A
ir
fl
o
w
o
b
st
ru
ct
io
n
’
p
-v
a
lu
e
G
e
n
d
e
r,
(%
M
al
e
)
(N
=
3
4
9
)*
3
6
.4
3
1
.6
4
0
.3
2
3
.1
4
8
.1
4
2
.6
0
.0
4
2
A
g
e
A
t
B
as
e
lin
e
(y
e
ar
s)
(n
=
3
4
5
)`
2
1
(1
8
)
4
0
(1
3
)
4
7
(1
0
)
4
3
(1
5
)
4
9
(1
6
)
5
0
(1
2
)
,
0
.0
0
1
A
g
e
A
t
O
n
se
t
O
f
Sy
m
p
to
m
s
(y
e
ar
s)
`
2
6
(1
9
)
1
3
(1
3
)
3
9
(1
4
)
2
7
(1
9
)
4
0
(1
8
)
2
5
(2
0
)
,
0
.0
0
1
B
M
I
(N
=
3
4
2
)`
2
9
(6
)
2
7
.9
(4
.4
3
)
3
6
(6
.2
)
2
7
(6
.3
9
)
2
6
.3
(5
.4
7
)
2
8
(5
.0
6
)
,
0
.0
0
1
P
ac
k
ye
ar
h
is
to
ry
(f
o
r
w
h
o
le
p
o
p
u
la
ti
o
n
)
(N
=
3
4
9
){
1
0
(1
5
)
4
(9
.5
)
1
2
(1
1
.5
)
1
0
(1
4
)
1
7
.5
(2
5
)
1
5
(1
0
)
0
.0
0
8
H
A
D
A
n
xi
e
ty
Sc
o
re
(N
=
1
6
0
){
8
(4
)
9
(7
.5
)
9
(4
)
4
.5
(4
)
8
(5
.5
)
6
(2
.7
5
)
0
.0
0
1
H
A
D
D
e
p
re
ss
io
n
Sc
o
re
(N
=
1
6
0
){
6
(4
)
6
(7
)
8
(5
)
2
.5
(3
)
4
.5
(3
.7
5
)
4
(5
.5
)
0
.0
0
2
P
C
2
0
M
e
th
ac
h
o
lin
e
ch
al
le
n
g
e
(N
=
2
0
){
1
(2
)
2
(2
)
2
(1
)
1
(3
)
1
(1
)
1
(1
)
0
.7
0
4
Ex
h
al
e
d
N
o
fl
o
w
ra
te
5
0
(N
=
1
2
4
){
3
7
(5
1
)
3
4
(4
5
)
5
1
(1
8
)
2
5
(2
9
)
5
5
(9
8
)
5
6
(8
9
)
0
.1
1
1
A
to
p
y
(%
Y
e
s)
(N
=
3
4
6
)*
5
8
.4
6
8
.7
6
1
.1
4
4
.2
5
3
.7
5
0
.9
0
.0
2
3
T
o
ta
l
Ig
E
b
lo
o
d
co
u
n
t,
kU
/l
(N
=
3
1
9
)`
3
0
3
(6
1
2
)
3
2
2
(3
6
1
)
1
5
1
(2
5
5
)
1
6
2
(1
8
6
)
6
3
8
(1
3
6
0
)
2
6
7
(2
5
3
)
,
0
.0
0
1
P
e
re
n
n
ia
l
rh
in
it
is
(%
Y
e
s)
(N
=
3
4
0
)*
2
9
.1
3
6
2
8
1
9
3
5
2
0
0
.0
8
8
Se
as
o
n
al
rh
in
it
is
(%
Y
e
s)
(N
=
3
4
0
)*
3
7
.9
4
8
3
8
3
3
3
0
3
1
0
.0
9
3
Ec
ze
m
a
(%
Y
e
s)
(N
=
3
4
1
)*
2
7
.9
4
1
2
8
1
9
1
7
2
0
0
.0
0
3
P
o
ly
p
s
(%
Y
e
s)
(N
=
3
4
0
)*
1
3
.5
1
2
1
3
1
2
2
0
1
4
0
.6
3
7
P
ri
o
r
n
as
al
su
rg
e
ry
(%
Y
e
s)
(N
=
3
4
0
)*
1
5
.0
2
0
1
3
9
.6
1
7
1
2
0
.4
2
3
R
e
fl
u
x
h
is
to
ry
(%
Y
e
s)
(N
=
3
4
0
)*
4
2
.6
5
1
4
7
2
7
3
2
4
6
0
.0
1
4
O
ra
l
st
e
ro
id
s
(Y
e
s
%
)
(N
=
3
4
7
)*
4
0
.9
5
1
5
6
6
1
7
5
7
,
0
.0
0
1
O
ra
l
st
e
ro
id
d
o
se
(m
g
)
(N
=
3
4
2
){
1
5
(1
0
)
1
5
(1
0
)
1
5
(1
0
)
8
(5
)
1
5
(1
0
)
1
0
(1
0
)
0
.1
5
3
B
D
P
e
q
u
iv
al
e
n
t
in
h
al
e
d
st
e
ro
id
d
o
se
(m
cg
)
(N
=
3
3
3
)`
1
8
5
3
(9
7
6
)
2
0
6
0
(9
9
5
)
2
1
0
0
(1
2
2
0
)
1
1
5
0
(6
3
3
)
1
7
7
0
(7
1
1
)
1
8
2
0
(7
2
0
)
,
0
.0
0
1
B
lo
o
d
Eo
si
n
o
p
h
il
co
u
n
t
1
0
9
/l
(N
=
3
2
7
){
0
.3
0
(0
.4
9
)
0
.2
8
(0
.4
1
)
0
.3
2
(0
.3
4
)
0
.2
0
(0
.2
7
)
0
.8
7
(1
.0
2
)
0
.2
1
(0
.4
0
)
,
0
.0
0
1
R
e
sc
u
e
st
e
ro
id
co
u
rs
e
s
in
la
st
ye
ar
(n
)
(N
=
3
2
2
){
4
(4
)
5
(4
.5
)
5
(3
)
1
(3
)
4
(4
)
0
(2
)
,
0
.0
0
1
H
o
sp
it
al
A
d
m
is
si
o
n
la
st
ye
ar
(n
)
(N
=
3
4
4
)`
1
(2
)
1
.8
(2
.6
)
1
.4
(2
.2
)
0
.8
(1
.3
)
1
.2
(1
.9
)
0
.4
(0
.8
)
,
0
.0
0
1
IT
U
ad
m
is
si
o
n
s
in
la
st
ye
ar
(N
=
3
4
5
)`
0
(1
)
0
.8
(1
.9
)
0
.3
(0
.7
)
0
.1
(0
.3
)
0
.1
(0
.5
)
0
.2
(0
.6
)
,
0
.0
0
1
IT
U
ad
m
is
si
o
n
e
ve
r
(%
ye
s)
(N
=
3
4
5
)*
1
8
.3
3
1
.9
1
6
.7
7
.7
9
.6
9
.4
,
0
.0
0
1
P
re
-b
ro
n
ch
o
d
ila
to
r
FE
V
1
(L
)
(N
=
3
3
8
)`
1
.9
5
(0
.8
2
)
1
.7
9
(0
.7
3
1
)
2
.2
5
(0
.6
4
9
)
2
.5
2
(0
.8
4
7
)
1
.7
5
(0
.8
8
1
)
1
.5
5
(0
.7
4
3
)
,
0
.0
0
1
P
re
-b
ro
n
ch
o
d
ila
to
r
FE
V
1
P
re
d
ic
te
d
(%
)
(N
=
3
3
0
)`
6
6
(2
4
)
5
8
.8
(2
1
.2
)
7
7
(1
9
.7
)
8
8
.4
(2
1
.1
)
5
8
.8
(2
0
.3
)
5
2
.8
(1
8
.9
)
,
0
.0
0
1
FE
V
1
/F
V
C
P
re
B
ro
n
ch
o
d
ila
to
r
(%
)
(N
=
3
2
9
)`
6
3
(1
5
)
5
8
.1
(1
4
.8
)
7
2
.5
(1
0
.9
)
7
6
.6
(9
.8
2
)
5
7
.5
(1
2
.3
)
5
3
.7
(1
2
.3
)
,
0
.0
0
1
P
o
st
-b
ro
n
ch
o
d
ila
to
r
FE
V
1
re
sp
o
n
se
(%
)
(N
=
2
3
9
)
1
8
.5
(2
3
.3
)
2
4
.8
(2
8
.5
)
1
2
.9
(1
2
.0
)
1
1
.3
(1
5
.0
)
1
9
.2
(3
0
.5
)
1
8
.8
(1
5
.8
)
0
.0
0
2
D
at
a
re
p
re
se
n
te
d
as
`
M
e
an
(S
D
)
te
st
e
d
w
it
h
A
N
O
V
A
te
st
,
{ M
e
d
ia
n
(I
Q
R
)
te
st
e
d
w
it
h
K
ru
sk
al
-W
al
lis
te
st
,
*(
%
)
te
st
e
d
w
it
h
C
h
i
sq
u
ar
e
d
te
st
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
2
9
8
7
.t
0
0
2
Cluster Analysis of the BTS Severe Asthma Registry
PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e102987
T
a
b
le
3
.
C
lu
st
e
r
sp
e
ci
fi
c
d
if
fe
re
n
ce
s
o
ve
r
ti
m
e
fo
r
cl
in
ic
al
ly
si
g
n
if
ic
an
t
o
u
tc
o
m
e
s
o
f
cl
u
st
e
rs
.
C
lu
st
e
r
1
‘E
a
rl
y
o
n
se
t,
a
to
p
ic
’
C
lu
st
e
r
2
‘O
b
e
se
,
la
te
o
n
se
t’
C
lu
st
e
r
3
‘n
o
rm
a
l
lu
n
g
fu
n
ct
io
n
le
a
st
se
v
e
re
a
st
h
m
a
’
C
lu
st
e
r
4
‘l
a
te
o
n
se
t,
e
o
si
n
o
p
h
il
ic
’
C
lu
st
e
r
5
‘A
ir
fl
o
w
o
b
st
ru
ct
io
n
’
p
-v
a
lu
e
d
if
fe
re
n
ce
b
e
tw
e
e
n
g
ro
u
p
s
D
if
fe
re
n
ce
P
-v
a
lu
e
D
if
fe
re
n
ce
P
-v
a
lu
e
D
if
fe
re
n
ce
P
-v
a
lu
e
D
if
fe
re
n
ce
P
-v
a
lu
e
D
if
fe
re
n
ce
P
-v
a
lu
e
B
M
I*
1
.2
(2
.6
)
,
0
.0
0
1
0
.2
(3
.0
)
0
.6
1
7
1
.6
(3
.4
)
0
.0
0
4
1
.4
(2
.3
)
,
0
.0
0
1
0
.8
(2
.3
)
0
.0
1
7
0
.0
5
1
P
re
b
ro
n
ch
o
d
ila
to
r
FE
V
1
`
0
.2
8
(0
.6
4
)
,
0
.0
0
1
2
0
.0
1
(0
.5
6
)
0
.9
4
3
2
0
.0
2
(0
.4
3
)
0
.7
5
4
0
.2
8
(0
.6
8
)
0
.0
0
8
0
.2
0
(0
.5
4
)
0
.0
3
1
0
.0
1
1
P
re
b
ro
n
ch
o
d
ila
to
r
FE
V
1
%
p
re
d
ic
te
d
`
1
1
.3
(2
1
.9
)
,
0
.0
0
1
2
.6
7
(1
8
.7
)
0
.2
7
5
0
.5
(1
5
.5
)
0
.8
4
8
1
2
.8
(2
5
.0
)
0
.0
0
2
1
0
.8
(1
9
.1
)
0
.0
0
1
0
.0
1
1
B
lo
o
d
Eo
si
n
o
p
h
il
co
u
n
t,
6
1
0
9
/l
`
2
0
.0
3
(0
.5
2
)
0
.5
7
5
2
0
.0
8
(0
.2
7
)
0
.0
4
6
0
.0
1
(0
.3
7
)
0
.9
4
1
2
0
.5
3
(0
.8
8
)
,
0
.0
0
1
2
0
.0
9
(0
.2
7
)
0
.0
9
,
0
.0
0
1
B
D
P
e
q
u
iv
al
e
n
t
(m
cg
/d
ay
)`
2
6
4
(9
8
9
)
0
.4
9
5
2
2
2
9
(1
2
0
5
)
0
.1
2
1
3
8
4
(8
8
4
)
0
.0
0
5
1
0
.6
(9
7
1
.3
)
0
.9
3
7
2
2
(8
5
2
)
0
.9
8
7
0
.0
3
2
%
o
n
st
e
ro
id
s
at
fo
llo
w
u
p
*
6
1
.5
%
0
.1
0
8
6
2
.0
%
0
.6
4
8
2
8
.0
%
0
.0
1
3
5
9
.3
%
,
0
.0
0
1
6
4
.2
%
0
.3
4
4
N
A
O
ra
l
st
e
ro
id
d
o
se
(m
g
){
2
0
.4
(1
6
.1
)
0
.8
6
8
0
.9
(1
2
.2
)
0
.6
7
9
0
(0
)
1
.0
5
.3
(2
1
.3
)
0
.5
3
5
0
.9
(1
0
.9
)
0
.6
7
0
0
.9
0
6
H
A
D
A
n
xi
e
ty
Sc
o
re
`
2
1
.2
(3
.1
)
0
.0
4
4
0
.0
(4
.6
)
1
.0
0
0
.3
(2
.2
)
0
.7
0
4
2
1
.3
(3
.6
)
0
.1
9
4
2
1
.3
(2
.7
)
0
.1
6
9
0
.5
5
7
H
A
D
D
e
p
re
ss
io
n
Sc
o
re
`
2
1
.0
(4
.4
)
0
.2
2
6
2
2
.1
(3
.5
)
0
.0
2
0
0
.1
8
(3
.1
)
0
.8
4
9
2
2
.0
7
(5
.0
)
0
.1
3
1
2
0
.7
(2
.7
)
0
.4
8
6
0
.5
4
8
R
e
sc
u
e
st
e
ro
id
co
u
rs
e
s
in
la
st
ye
ar
(n
){
2
2
(2
6
to
0
)
,
0
.0
0
1
2
2
(2
4
to
1
)
0
.0
0
4
0
.5
(2
2
to
2
)
0
.9
0
3
2
2
(2
5
to
0
)
,
0
.0
0
1
1
(0
to
3
)
0
.0
2
7
,
0
.0
0
1
D
at
a
re
p
re
se
n
te
d
as
`
M
e
an
(S
D
)
te
st
e
d
w
it
h
p
ai
re
d
t-
te
st
fo
r
e
ac
h
cl
u
st
e
r,
{ M
e
d
ia
n
(I
Q
R
)
te
st
e
d
w
it
h
p
ai
re
d
sa
m
p
le
W
ilc
o
xo
n
si
g
n
e
d
ra
n
k
te
st
,
*
(%
)
te
st
e
d
w
it
h
M
cN
e
m
ar
’s
te
st
.
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
o
n
e
.0
1
0
2
9
8
7
.t
0
0
3
Cluster Analysis of the BTS Severe Asthma Registry
PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e102987
treated with oral corticosteroids increased in all groups with
statistically significant increases for clusters 3 and 4. This was
coupled with a concomitant increase in BMI, which was
statistically significant in all but cluster 2. Clusters 1, 4 and 5
had statistical improvement in forced expiratory volume in 1
second (FEV1) Mean (SD) 0.28 (0.64), 0.28 (0.68), 0.20 (0.54)
respectively. There was a statistically significant decrease in
exacerbation frequency in clusters 1, 2 and 4 median (IQR) 22
(26,20), 22 (24, 1), 22 (25, 0) respectively with an associated
improvement in the Hospital Anxiety and Depression (HAD) score
in clusters 1 for anxiety mean (SD) 21.2 (3.1) and 2 for depression
mean (SD)22.1 (3.5). The peripheral blood eosinophil counts in
clusters 2 and 4 mean (SD), 20.08 (0.27), 20.53 (0.88)
respectively.
The classifier produced 79% correct cluster membership when
compared with original cluster membership at baseline (Table 4)
with Cluster 2 being the best predicted and Clusters 1 and 4 being
predicted well. The classifier was used on data from the follow-up
time point to determine if clusters remained consistent over time.
The classification at the next time point compared to the baseline
clustering was 52% (Table 5). Patients that were originally in
cluster 2, the obese asthmatic group, were the most consistent over
time. The largest changes were that a substantial proportion of the
patients in clusters 1, 4, and 5 moved into clusters 2 and 3 at follow
up reflecting the changes in lung function, peripheral blood
eosinophilia and exacerbation frequency.
The classifier was also used to classify data on the new dataset of
245 severe refractory asthma patients presenting to seven specialist
centres including the 4 original centres. These new patients
received a cluster annotation. The clusters were in similar
proportions in the new dataset and shared similar properties to
the original cohort (Table 6).The proportions of subjects in each
cluster were different across the centres (Table E2 in File S1). The
cluster specific variables were tested between each dataset to
determine cluster similarities across the two datasets (Table E3 in
File S1).
Discussion/Conclusions
We describe here for the first time the application of statistical
clustering in a multi-centre longitudinal observational study of the
British Thoracic Society Severe refractory Asthma Registry. To
date this is the largest group of severe refractory asthma patients to
be included in a cluster analysis. Five clusters were identified and
Figure 1. Differences in clinical outcomes between baseline and follow-up for each cluster. Pre Bronchodilator FEV1 % predicted and
Blood eosinophil count statistics are Mean (+/2SD). Exacerbation frequency outcomes are median (IQR) and percentage on oral steroids are
percentages.
doi:10.1371/journal.pone.0102987.g001
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using a classifier we have validated these clusters in an
independent cohort of patients submitted to the Registry. We
have determined phenotypic-specific changes over time and
applied the classifier to report for the first time cluster membership
stability over time, when treatment is optimised. Stability of cluster
membership at follow-up was 52% for the whole group ranging
from 25–71% within clusters. Therefore, statistical cluster analysis
can identify distinct phenotypes with specific outcomes, but the
stability of cluster membership is poor.
The clusters were obtained by carrying out statistical mixture
models, where a different number of clusters are tried iteratively
and compared using the model fitting criteria Akaike information
criterion and the Bayesian information criterion to obtain the
statistically best fitting number of clusters. This clustering method
allows the number of clusters to be obtained objectively rather
than relying on graphs or expert opinion. The five clusters
identified were Cluster 1 (34%) the most atopic with early onset
disease, cluster 2 (21%) obese with late onset disease, cluster 3
(15%) least severe disease, cluster 4 (15%) the most eosinophilic
with late onset disease and cluster 5 (15%) severe airflow
obstruction. To further validate these clusters a classifier was
created to predict cluster membership for the original dataset and
was applied to a new dataset of independent patients recruited to
the British Thoracic Society Severe refractory Asthma Registry.
This classifier was able to assign cluster membership with 79%
accuracy. The 5 clusters in the validation group were of similar
proportions and had very similar clinical characteristics.
It is worth noting that all conclusions from the data are found
using the cluster and classifier methodology. We present an un-
biased statistical cluster analysis technique which selects the
number of clusters based on the fit if the data. Bias could come
from the choice of variables to include in the cluster analysis we
chose asthma related-variables that had minimal missing values.
The classifier plays a crucial role in monitoring asthma stability,
we used the classifier that best derived the clusters from the data to
obtain the best results for all clusters but the conclusions are
limited to the accuracy of the classifier which was good in this case.
Although cluster instability could be due to many factor such as
cluster methodology, classifier accuracy, underlying disease
variability or response to treatment. The cluster instability we
found was associated with the clinical characteristics in patients in
clusters significantly changing over follow up. This significant
change caused them to look like other cluster characteristics found
at baseline, suggesting that the cause of cluster instability is due to
either the disease variability or response to treatment and not due
to statistical methodology.
Our confidence that these clusters are robust is also derived
from comparison with other clusters described in the literature.
The first multi-centre cluster analysis of asthma undertaken in
North America the Severe Asthma Research Network (SARP) [6]
also found 5 clusters, but only 3 of these represented patients with
severe disease. There were similarities with our clusters with the
identification of an obese female predominant cluster, a cluster
with moderate airflow obstruction and another with severe airflow
obstruction. In the first cluster analysis of severe asthma
undertaken in a single-centre study in Leicester, UK Haldar et
al [5] also described 5 clusters annotated as ‘early-onset atopic’,
‘obese female’, ‘benign asthma’, ‘inflammation predominant’ and
‘early symptom predominant’, which was replicated in an
independent group of patients from the same centre [7]. The first
4 clusters match extremely well with the clusters described here in
this multi-centre study. Spirometry was not included in the cluster
Table 4. Cluster and Classification membership compared at baseline.
Predicted cluster classification for baseline data
Baseline
cluster
Cluster 1 ‘Early
onset, atopic’
Cluster 2 ‘Obese,
late onset’
Cluster 3 ‘normal
lung function least
severe asthma’
Cluster 4 ‘late
onset, eosinophilic’
Cluster 5 ‘Airflow
obstruction’
1 80.0 7.1 5.9 3.5 3.5
2 4.4 88.9 2.2 4.4 0.0
3 2.6 10.3 74.4 2.6 10.3
4 5.3 2.6 2.6 86.8 2.6
5 16.7 10.0 13.3 0.0 60.0
doi:10.1371/journal.pone.0102987.t004
Table 5. Cluster memberships at baseline compared to classification membership at follow up.
Predicted clusters from year follow up data
Baseline
cluster
Cluster 1 ‘Early
onset, atopic’
Cluster 2 ‘Obese,
late onset’
Cluster 3 ‘normal lung
function least severe
asthma’
Cluster 4 ‘late onset,
eosinophilic’
Cluster 5 ‘Airflow
obstruction’
1 52.2 15.2 10.9 13.0 8.7
2 3.2 71.0 12.9 3.2 9.7
3 6.7 40.0 46.7 6.7 0.0
4 25.0 15.0 15.0 25.0 20.0
5 12.5 18.8 18.8 0.0 50.0
doi:10.1371/journal.pone.0102987.t005
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analysis in the Haldar et al study and we did not have data for the
asthma control questionnaire in sufficient subjects to include in the
analysis and this is likely to explain the small differences in cluster
characteristics between these studies. Taken together these studies
do suggest that cross-sectionally these cluster phenotypes are
robust across western European and North American populations
of refractory/severe asthma, although importantly the proportions
vary between centres which is likely a reflection of referral
patterns, but possibly due to real geographical differences.
Interestingly, recent data from a multi-centre Korean study
identified four refractory asthma clusters [8] that were mostly
different to our study or the previously reported UK and USA
studies suggesting possible influences of geography and ethnicity.
The potential utility of the identification of refractory/severe
asthma clusters is whether they represent distinct endotypes with
different underlying aetiology and immunopathogenesis and
whether they predict responses to therapy and natural history
([1,3], and [4]). We did not investigate the potential immunolog-
ical or pathophysiological mechanisms for the clusters and this
warrants further investigation. The patients were managed
clinically and follow-up data was available at a single time point
with a median time of follow-up of 3 years. At follow-up the
proportion of subjects treated with oral corticosteroids increased in
all groups with significant increases for cluster 3 and 4. This was
coupled with a concomitant increase in BMI, which was significant
in all but cluster 2. Clusters 1, 4 and 5 had statistical improvement
in FEV1, but this change was not closely associated with changes
in therapy or peripheral blood eosinophil count. The disconnect
between eosinophilic inflammation and lung function is well
described [4], but the inconsistency between improvement in lung
function and increased therapy may reflect changes in adherence
to therapy during the study, which was not formally assessed
across centres, or perhaps in part due to regression towards the
mean in the clusters with more impaired lung function.
Exacerbation frequency decreased significantly in clusters 1, 2,
and 4 and was associated with a significant fall in the peripheral
blood eosinophil count in clusters 2 and 4 and a small non-
significant decrease in cluster 1. In contrast, in cluster 5 there was
a fall in the eosinophil count with a small increase in exacerbation
frequency, but this small increase in exacerbation frequency is
perhaps more likely to reflect regression to the mean than a
clinically important difference. An association between eosino-
philic inflammation and exacerbations is consistent with previous
observations that eosinophilic inflammation is a good predictor of
response to corticosteroid therapy [29] and interleukin-5 mono-
clonal antibody therapy [30,31], and that the reduction in
exacerbation frequency is also related to the reduction in
peripheral blood eosinophilia.
Cluster membership stability was assessed at follow-up using the
classifier. This was 52% for the whole group with stability being
best in cluster 2 (71%) and worst in cluster 4 (25%). The largest
changes were that a substantial proportion of the patients in
clusters 1, 4, and 5 moved into clusters 2 and 3 at follow up
reflecting improvements in lung function, peripheral blood
eosinophilia, and exacerbation frequency with increasing obesity.
The instability of the cluster membership is perhaps unsurprising
in a disease characterised by variability over time and in a real
world study in which interventions are instigated as per clinical
guidelines rather than in a controlled study. This is not
problematic when the instability of the phenotype is used to
direct therapy at the time of an assessment for example with the
use of a sputum eosinophilia to titrate corticosteroid therapy [32].
However, if emerging phenotype-specific therapies [33] require
knowledge of phenotype stability within a patient this will require
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an understanding of the dynamics of a patient’s phenotype using
repeated assessments over time and possibly in response to
exacerbation events and therapeutic interventions.
One major criticism of this study is that although several
domains of the disease were assessed the asthma control and
quality of life measures were not recorded systematically in all
centres and therefore were insufficient for inclusion in this analysis.
Changes in asthma control have a substantial impact upon
morbidity and clinical decisions and their absence here does limit
interpretation of why therapies were changed in some of the
clusters. There is increasing recognition that poor adherence is
common in severe refractory asthma, although its identification
and management is complex [34]. The disconnect between some
of the clinical outcomes and change in therapy would have been
better informed in light of adherence rates in the clusters.
Importantly, cluster membership is defined by what is measurable
at the time of the study. In order to unlock other possible sub-
groups or verify cluster immunopathogenesis data at other scales
of the disease for example from tissue samples, sputum, protein or
transcriptomic signatures from the host and analysis of environ-
mental exposure such as the microbiome may shed more light
upon the mechanisms driving the clusters. Although this report is
amongst the largest groups of severe asthmatics studied our
findings still require further validation in larger populations across
different geographical locations with different health care systems.
In particular, we found differences across centres in a single
country and the reasons for this variability needs to be
investigated. Additionally, the follow-up was limited to a single
assessment and further work more carefully examining the
dynamics of the severe refractory asthma phenotypes are required.
In conclusion, statistical clustering of the British Thoracic
Society Severe refractory Asthma Registry identified 5 clusters that
were validated in an independent dataset and had many
similarities with earlier algorithmic cluster analyses. Follow-up of
these clusters demonstrated phenotype-specific outcomes and
consequently considerable cluster instability overtime supporting
the view that severe refractory asthma is a homeokinetic as well as
heterogeneous condition. Understanding this heterogeneity over
time remains an important challenge to advance stratified
medicine.
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